Literature DB >> 18589334

Factors associated with the steep increase in late-midlife stroke occurrence among US men.

Amytis Towfighi1, Jeffrey L Saver, Rita Engelhardt, Bruce Ovbiagele.   

Abstract

BACKGROUND: Data on recent stroke prevalence rates among middle-aged men in the United States indicate that men aged 55 to 64 years are 3 times more likely than men aged 45 to 54 years to have experienced a stroke. We aimed to determine potential risk factors that may contribute to this steep increase in late midlife stroke occurrence.
METHODS: We analyzed the National Health and Nutrition Examination Survey 1999 to 2004 data sets, assessing stroke prevalence, predictors of stroke occurrence, and vascular risk factors in men across their midlife years.
RESULTS: Crudely, higher glycohemoglobin, history of hypertension, history of diabetes, and history of coronary artery disease significantly predicted stroke in 45- to 54- and 54-to 64-year-old men. Significant stroke risk factors unique to each age group were non-white race, lower ankle-brachial pulsatility index, and occurrence of recent severe headache in the 45- to 54-year age group, whereas elevated serum homocysteine (HCY) level predicted stroke in those aged 55 to 64 years. In multivariable regression analysis, lower ankle-brachial pulsatility index (odds ratio [OR] 1.69, 95% confidence interval [CI] 1.47-1.83, P < .001) and recent severe headache (OR 5.12, 95% CI 1.3-20.1, P = .019) were the only independent predictors of stroke in the 45- to 54-year age group, whereas only elevated HCY predicted stroke in the 55- to 64-year age group (OR 1.708, 95% CI -1.103-2.643, P = .0163).
CONCLUSION: Elevated serum HCY level is the sole independent predictor of stroke among men aged 55 to 64 years in the United States. Further study to assess the efficacy of HCY-lowering treatment in mitigating a steep increase in late midlife stroke occurrence among men may be warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589334      PMCID: PMC2728439          DOI: 10.1016/j.jstrokecerebrovasdis.2007.12.007

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  12 in total

1.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Stroke       Date:  2006-02       Impact factor: 7.914

2.  Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study.

Authors:  J K Virtanen; S Voutilainen; G Alfthan; M J Korhonen; T H Rissanen; J Mursu; G A Kaplan; J T Salonen
Journal:  J Intern Med       Date:  2005-03       Impact factor: 8.989

3.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Wayne Rosamond; Katherine Flegal; Gary Friday; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Michael Ho; Virginia Howard; Brett Kissela; Bret Kissela; Steven Kittner; Donald Lloyd-Jones; Mary McDermott; James Meigs; Claudia Moy; Graham Nichol; Christopher J O'Donnell; Veronique Roger; John Rumsfeld; Paul Sorlie; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Yuling Hong
Journal:  Circulation       Date:  2006-12-28       Impact factor: 29.690

4.  Validity of self-reported stroke : The Tromso Study.

Authors:  T Engstad; K H Bonaa; M Viitanen
Journal:  Stroke       Date:  2000-07       Impact factor: 7.914

5.  Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial.

Authors:  P Dusitanond; J W Eikelboom; G J Hankey; J Thom; G Gilmore; K Loh; Q Yi; C J M Klijn; P Langton; F M van Bockxmeer; R Baker; K Jamrozik
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

6.  Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study.

Authors:  Jyrki K Virtanen; Sari Voutilainen; Pertti Happonen; Georg Alfthan; Jari Kaikkonen; Jaakko Mursu; Tiina H Rissanen; George A Kaplan; Maarit J Korhonen; Juhani Sivenius; Jukka T Salonen
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2005-08

7.  Homocysteine lowering with folic acid and B vitamins in vascular disease.

Authors:  Eva Lonn; Salim Yusuf; Malcolm J Arnold; Patrick Sheridan; Janice Pogue; Mary Micks; Matthew J McQueen; Jeffrey Probstfield; George Fodor; Claes Held; Jacques Genest
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

8.  Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Authors:  Kaare Harald Bønaa; Inger Njølstad; Per Magne Ueland; Henrik Schirmer; Aage Tverdal; Terje Steigen; Harald Wang; Jan Erik Nordrehaug; Egil Arnesen; Knut Rasmussen
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

Review 10.  Homocysteine-lowering therapy: a role in stroke prevention?

Authors:  J David Spence
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

View more
  6 in total

1.  Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Matteo N D Di Minno; Nicholas S Kirkby; Timothy D Warner; Giovanni Di Minno; Giuseppe Cirino; Raffaella Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

2.  Headache and biomarkers predictive of vascular disease in a representative sample of US children.

Authors:  Karin B Nelson; Amanda Kalaydjian Richardson; Jianping He; Tarranum M Lateef; Suzan Khoromi; Kathleen R Merikangas
Journal:  Arch Pediatr Adolesc Med       Date:  2010-04

Review 3.  Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties.

Authors:  Federico Cacciapuoti
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

4.  Headache after ischemic stroke: A systematic review and meta-analysis.

Authors:  Andrea M Harriott; Fahri Karakaya; Cenk Ayata
Journal:  Neurology       Date:  2019-11-06       Impact factor: 9.910

5.  Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patients, especially elderly males.

Authors:  Takafumi Okura; Ken-Ichi Miyoshi; Jun Irita; Daijiro Enomoto; Tomoaki Nagao; Masayoshi Kukida; Akiko Tanino; Kayo Kudo; Zouwei Pei; Jitsuo Higaki
Journal:  Sci Rep       Date:  2014-07-11       Impact factor: 4.379

6.  Metabolomics analysis reveals an effect of homocysteine on arachidonic acid and linoleic acid metabolism pathway.

Authors:  Bin Li; Guangqiang Gao; Wanying Zhang; Bowen Li; Chun Yang; Xiaofeng Jiang; Yaping Tian; Hongyan Liang
Journal:  Mol Med Rep       Date:  2018-02-27       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.